Hi hear you Ahjay. I'm certainly frustrated. As we have...

Hi hear you Ahjay. I'm certainly frustrated. As we have discussed many times, it's doubly frustrating when companies like our friends at IMU. NEU has also performed strongly, while PTX and OPT are also up from their lows.

While I was little frustrated that more trials just further draws out times to approval, there are also a few benefits. More combinations will hopefully build competitive tension and further demonstrating Efti's effectiveness to BP. One thing that needs to be remembered from Viralytics days was that VLA had trials going with both BMS (Yervoy) and MSD (Keytruda) and getting good results with both.